NICE drug reviews overhauled to speed up access

NICE will begin publishing assessments of medicines that are not yet available in the UK later this month, in order to help inform commissioners' planning decisions.

Medicines will be assessed by NICE before launch to help commissioners
Medicines will be assessed by NICE before launch to help commissioners

The move forms part of the institute’s efforts to accelerate patient access to medicines and will be the first time drugs have been assessed before being launched in the UK.

Last year, GP revealed that many PCTs maintain a policy that all newly licensed drugs are added to blacklists until they have been appraised by NICE.

NICE’s evidence summaries for new medicines (ESNMs) for October will include the long-acting insulin analogue degludec. In January NICE will publish an evidence summary about the once-daily glucagon-like peptide-1 receptor agonist lixisenatide. Neither degludec nor lixisenatide has yet been launched in the UK.

NICE has also issued its first recommendations this week as part of its review on the use of unlicensed and off-label medicines. The first topic covered as part of these reviews is the use of tranexamic acid for significant haemorrhage following trauma.

A NICE spokesman said ESNMs summarised evidence on new medicines considered to be of significance to the NHS and would be a useful resource for commissioners.

‘Topics for ESNM will be considered either at the point of product launch, or up to 12 months in advance of launch,’ he said. ‘The strengths and weaknesses of the relevant evidence will be critically reviewed within this summary.’

He stressed that ESNMs would not constitute formal NICE guidance and this would be clearly stated on each publication.

‘There are restrictions on the promotion of new medicines to clinicians before receipt of a marketing authorisation,’ he said. ‘The information in our ESNMs on drugs that are still awaiting UK marketing authorisation is provided to clinicians for use for planning purposes in their role as commissioners.’

A spokesman for Sanofi, which manufatures lixisenatide, said the company was 'content' to work with NICE's medicines and prescribing centre (MPC) on the evidence summaries.

'We have worked with National Prescribing Centre (predecessor to MPC) for many years on this type of early product summary,' he said.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Practices handed one-month opt-out window as revamped network DES unveiled

Practices handed one-month opt-out window as revamped network DES unveiled

NHS England has unveiled a revamped DES package for 2020/21 confirming new targets,...

GPs delivered huge rise in face-to-face consultations in week before NHS England letter

GPs delivered huge rise in face-to-face consultations in week before NHS England letter

GPs delivered a huge increase in face-to-face appointments in the week before NHS...

RCGP facing legal action over stance on assisted dying

RCGP facing legal action over stance on assisted dying

The RCGP is facing legal action over its decision to remain opposed to assisted dying...

Medeconomics Live aims to help practices thrive under the new GP contract

Medeconomics Live aims to help practices thrive under the new GP contract

The one-day, virtual Medeconomics Live conference aims to provide practices with...

GPs face wave of abuse and complaints after NHS England face-to-face appointments claims

GPs face wave of abuse and complaints after NHS England face-to-face appointments claims

GP practices have faced a wave of abuse and complaints after a letter from NHS England...

Government denies plan to make GPs 'gatekeepers' of COVID-19 testing

Government denies plan to make GPs 'gatekeepers' of COVID-19 testing

The government has denied plans to make GPs 'gatekeepers' of the struggling COVID-19...